Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.40 |
| ▸ | FAP | Q12884 | 3/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460226 | 0.83 | RIPK1 (0.37) | FAPPREPDPP4 | |
| SCHEMBL20055272 | 0.82 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21319546 | 0.79 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20663620 | 0.79 | DPP4 (0.40) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL27879636 | 0.79 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15392569 | 0.78 | HPGD (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19890684 | 0.77 | SRC (0.42) | DPP4DPP8DPP9 | |
| SCHEMBL29099425 | 0.77 | THRB (0.45) | CHRM1 | |
| SCHEMBL24244444 | 0.76 | DPP4 (0.34) | PREPDPP4DPP8DPP9 | |
| SCHEMBL12208420 | 0.76 | CYP3A4 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3309157-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2364148-B1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20160287553-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-10-06 | — | — | US | disclosed |
| US-9387192-B2 | Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer | DKFZ DEUTCHERS KREBSFORSCHUNGSZENTRUM (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20160158189-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-09 | — | — | US | disclosed |
| WO-2015075165-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015007714-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-20110250166-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2011-10-13 | — | — | US | disclosed |
| WO-2010057981-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2010-05-27 | — | — | WO | disclosed |
| EP-2189158-A1 | Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer | DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1377549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CHRM2 4881/4885CHRM4 4849/4885CHRM5 4859/4885 |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CHRM2 1619/4885CHRM4 1365/4885CHRM5 1602/4885 |
| US-20110250166-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | BAD, BID, CASP2 | CHRM2 4334/4885CHRM4 4175/4885CHRM5 4467/4885 |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CHRM2 1483/4885CHRM4 1170/4885CHRM5 1461/4885 |
| US-20160287553-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | EIF4E, EIF4EBP1, EIF5B | CHRM2 4875/4885CHRM4 4885/4885CHRM5 4707/4885 |
| US-20160158189-A1 | SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES | CASP5, API5, BAX | CHRM2 4790/4885CHRM4 4643/4885CHRM5 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.